drugset / Trial / NCT06493799
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
RandomizedParallel-groupDouble-blindTreatment
Summary
Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)
Timeline
- Start
- 2024-07-01
- Primary completion
- 2026-03-31
- Completion
- 2026-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LAENNEC | Unknown | 4 ml | Intravenous |
| Subject | LAENNEC | Unknown | 10 ml | Intravenous |